Some Comments Posted on the ABC News Blog About the President’s Failure to Light the White House Blue for Prostate Cancer

Referring back to last Friday’s post asking that you share your comments on the ABC News Blog About the President’s failure to light the White House Blue, here are just a few of the many that were posted: Why politicize breast cancer? Every kind of cancer is horrible. Last month (September) was prostate cancer awareness [...]

Share Your Comments About the Failure of the White House to Acknowledge Prostate Cancer Awareness Month

I apologize for the lack of posts but I just returned from Virginia where I served as an ad hoc reviewer for U.S. Army Medical Research and Materiel Command (USAMRMC) Prostate Cancer Research Program (PCRP) aka the Congressionally Directed medical Research Program. We spent two very intensive days reviewing prostate cancer research grant applications from [...]

Testimony of James L. Mohler, MD Before the Senate Committee on Foreign Relations The Al-Megrahi Release: One Year Later

Expert opinion about the “three months to live” prognosis Scottish physicians gave Abdelbaset Ali Mohmed al-Megrahi in August 2009. September 29, 2010 “Based on the medical report issued by the Scottish authorities, I believe that three-month prognosis was medically unjustifiable. Any physician with any training or experience in treating prostate cancer would have known that [...]

Androgen deprivation therapy for prostate cancer: Recommendations to improve patient and partner quality of life

Written by our own Richard Wassersug appearing in UroToday.com BERKELEY, CA (UroToday.com) – Much has happened with the use of androgen deprivation to treat prostate cancer (PCa) patients since Charles Huggins first castrated a patient in order to alleviate the symptoms of advanced PCa. Back then, patients were generally elderly and symptomatic with either urethral [...]

Sodium Clodronate Improves Survival In Patients With Advanced Prostate Cancer But Not With Localized Disease

An article published Online First and in an upcoming edition of The Lancet Oncology reports that an oral bisphosphonate, sodium clodronate, improves overall survival in men with advanced prostate cancer. However, it does not reduce the risk of death in men with localized disease. These are the final results of the MRC PR05 and MRC [...]

Go to Top